David Grinblatt to Survival Rate
This is a "connection" page, showing publications David Grinblatt has written about Survival Rate.
Connection Strength
0.061
-
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
Score: 0.017
-
Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? Bone Marrow Transplant. 2006 Jul; 38(2):95-100.
Score: 0.013
-
Autologous and allogeneic transplantation for aggressive NHL. Cytotherapy. 2002; 4(3):223-40.
Score: 0.010
-
A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma. Cancer. 1998 Oct 15; 83(8):1540-5.
Score: 0.008
-
High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience. Bone Marrow Transplant. 1998 Jan; 21(2):127-32.
Score: 0.007
-
Phase II study of intravenous melphalan (NSC-8806) in the treatment of patients with advanced squamous carcinoma of the head and neck. Invest New Drugs. 1994; 12(1):45-7.
Score: 0.006